Semaglutide CAS 910463-68-2

Semaglutide, a long-acting analogue of human glucagon-like peptide-1 (GLP-1) receptor, is an agonist for the human glucagon-like peptide-1 (GLP-1) receptor and is clinically useful for the treatment of type 2 diabetes.

Retatrutide is a triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulin-stimulating polypeptide receptor (GIPR), and glucagon like peptide-1 receptor (GLP-1R).

Retatrutide inhibited human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively.

Retatrutide can be used in obesity research.

 

Semaglutide is a long-acting formulation based on the basic structure of liraglutide that is more effective in the treatment of type 2 diabetes. Therefore, it is mainly used in the medical field and clinical research.

Semaglutide is a drug similar to glucagon-like peptide-1 (GLP-1). It is primarily used in the treatment of type 2 diabetes and has shown many benefits and effects:
1. Blood sugar control: Semaglutide lowers blood sugar levels by regulating the secretion of insulin and glucagon. When blood sugar levels are high, it can promote the secretion of insulin, thus lowering blood sugar; It also stimulates the secretion of glucagon to avoid hypoglycemia when the risk of hypoglycemia may occur.
2. weight loss: Semaglutide helps suppress appetite, increase satiety and help patients lose weight. For patients with type 2 diabetes, which is often associated with obesity, this effect of Semaglutide has positive implications for improving the condition.
3.Improve insulin resistance: Semaglutide can improve insulin sensitivity and reduce insulin resistance, thereby improving insulin utilization efficiency and maintaining stable blood sugar.

The factories we cooperate with have large shipments of Semaglutide, rapid delivery and fresh production dates. This can help some suppliers and buyers to buy high-quality Semaglutide with fresh production date from us. We will not sell products near the expiration date to customers like others, because transportation takes time, so our delivery cycle is usually arranged in 10-15 days, and orders under 10 tons will be shipped within 10 days.

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist, selectively binding to and activating GLP-1 receptors (natural GLP-1 targets). GLP-1 is a physiological hormone mediated by GLP-1 receptor that has multiple effects on glucose. The main mechanism leading to the prolonged half-life of semaglutide is albumin binding, which leads to reduced renal clearance and prevents metabolic degradation. In addition, Semaglutide was stable against the degradation of DPP-4 enzyme.

Semaglutide lowers blood sugar through mechanisms that stimulate insulin secretion and decrease glucagon secretion, both of which occur in a glucose-dependent manner. Therefore, when blood sugar is high, insulin secretion is stimulated and glucagon secretion is suppressed. The mechanism for lowering blood sugar also involves a slight delay in gastric emptying early after a meal.